San Francisco, CA – May 18, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a ...
The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission granted Marketing ...
Shire Receives Approvable Letter From FDA for Intuniv (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, June 21, 2007 -- ...
Every time Toketemu publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Clonidine and Guanfacine belong to a class of medications known as alpha-2 adrenergic agonists. Originally developed to treat high blood pressure, these medications have been found effective in ...
October marks ADHD Awareness Month, aimed at increasing understanding and reducing stigma surrounding Attention-Deficit/Hyperactivity Disorder (ADHD), a problem that affects both adults and children b ...
"The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback